Synthesis and evaluation of structurally constrained quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.

A series of structurally constrained derivatives of the potent H 3 inverse agonist 1 was designed, synthesized, and evaluated as histamine H 3 receptor inverse agonists. As a result, the N-cyclobutylpiperidin-4-yloxy group as in 2f was identified as an optimal surrogate structure for the flexible 1-pyrrolidinopropoxy group of 1. Subsequent optimization of the quinazolinone core of 2f revealed that substitution at the 5-position of the quinazolinone ring influences potency. Representative derivatives 5a and 5s showed improved potency in a histamine release assay in rats and a receptor occupancy assay in mice.

[1]  H. Kotani,et al.  Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. , 2006, Journal of pharmacological sciences.

[2]  L Landais,et al.  BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, Hydrochloride], a Nonimidazole Inverse Agonist/Antagonist at the Human Histamine H3 Receptor: Preclinical Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[3]  H. Niwa,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector. , 1991, Gene.

[4]  R. Yoshimoto,et al.  Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists. , 2008, Journal of medicinal chemistry.

[5]  Masahiko Sato,et al.  Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[6]  M. Berlin,et al.  Recent advances in the development of histamine H3 antagonists , 2007, Expert opinion on therapeutic patents.

[7]  Y. Masuho,et al.  Molecular Cloning and Characterization of a Novel Type of Histamine Receptor Preferentially Expressed in Leukocytes* , 2000, The Journal of Biological Chemistry.

[8]  S. Hastrup,et al.  Characteristics of recombinantly expressed rat and human histamine H3 receptors. , 2002, European journal of pharmacology.

[9]  Rob Leurs,et al.  Keynote review: histamine H3 receptor antagonists reach out for the clinic. , 2005, Drug discovery today.

[10]  O. Mitsunobu.  THE USE OF DIETHYL AZODICARBOXYLATE AND TRIPHENYLPHOSPHINE IN SYNTHESIS AND TRANSFORMATION OF NATURAL PRODUCTS , 1981 .

[11]  G. Fox,et al.  Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. , 2006, Molecular interventions.

[12]  R. Leurs,et al.  Histamine H3 receptor ligands break ground in a remarkable plethora of therapeutic areas , 2007, Expert opinion on investigational drugs.

[13]  J. Sullivan,et al.  4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention. , 2005, Journal of medicinal chemistry.

[14]  J. Arrang,et al.  Constitutive activity of the histamine H3 receptor. , 2007, Trends in pharmacological sciences.

[15]  Michael A. Briggs,et al.  GSK189254, a Novel H3 Receptor Antagonist That Binds to Histamine H3 Receptors in Alzheimer's Disease Brain and Improves Cognitive Performance in Preclinical Models , 2007, Journal of Pharmacology and Experimental Therapeutics.

[16]  J. Schwartz,et al.  Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. , 2007, Biochemical pharmacology.

[17]  D. Hughes,et al.  PROGRESS IN THE MITSUNOBU REACTION. A REVIEW , 1996 .

[18]  C. Rizzo,et al.  Coordination of Histamine H3 Receptor Antagonists with Human Adrenal Cytochrome P450 Enzymes , 2002, Pharmacology.

[19]  B. Malinowska,et al.  Modulation of neurotransmitter release via histamine H3 heteroreceptors , 1994, Fundamental & clinical pharmacology.

[20]  Thomas R. Miller,et al.  Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties , 2005, Journal of Pharmacology and Experimental Therapeutics.

[21]  J. Arrang.  Pharmacological properties of histamine receptor subtypes. , 1994, Cellular and molecular biology.

[22]  C. Dvorak,et al.  Recent medicinal chemistry of the histamine H3 receptor. , 2006, Progress in medicinal chemistry.

[23]  Holger Stark,et al.  High constitutive activity of native H3 receptors regulates histamine neurons in brain , 2000, Nature.

[24]  H. Schaffhauser,et al.  Correlation between ex Vivo Receptor Occupancy and Wake-Promoting Activity of Selective H3 Receptor Antagonists , 2008, Journal of Pharmacology and Experimental Therapeutics.

[25]  D. Macneil,et al.  Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor. , 2006, European journal of pharmacology.

[26]  Craig W Berridge,et al.  4-phenoxypiperidines: potent, conformationally restricted, non-imidazole histamine H3 antagonists. , 2005, Journal of medicinal chemistry.

[27]  S. Botros,et al.  Synthesis, anti-hypertensive and β-adrenoreceptor antagonist activities of 3-[4-[3-(4-aryl-1-piperazinyl)-isopropanoloxy]-phenyl]-4(3H quinazolones , 1989 .

[28]  R. Leurs,et al.  [3H]‐thioperamide as a radioligand for the histamine H3 receptor in rat cerebral cortex , 1996, British journal of pharmacology.

[29]  Min Zhang,et al.  Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H 3 Receptor Antagonist , 2005 .

[30]  J. Hochman,et al.  In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. , 2001, The Journal of pharmacology and experimental therapeutics.

[31]  G R Lankas,et al.  Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. , 1997, Toxicology and applied pharmacology.

[32]  J. Schwartz,et al.  Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor , 1983, Nature.

[33]  R. Leurs,et al.  The histamine H3 receptor: from gene cloning to H3 receptor drugs , 2005, Nature Reviews Drug Discovery.

[34]  G R Lankas,et al.  P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. , 1997, Toxicology and applied pharmacology.

[35]  G. Glavin,et al.  H3 receptor antagonist, thioperamide, inhibits adrenal steroidogenesis and histamine binding to adrenocortical microsomes and binds to cytochrome P450 , 1992, British journal of pharmacology.

[36]  J. Witkin,et al.  Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. , 2004, Pharmacology & therapeutics.

[37]  M. Jackson,et al.  Cloning and functional expression of the human histamine H3 receptor. , 1999, Molecular pharmacology.

[38]  H. Haas,et al.  The physiology of brain histamine , 2001, Progress in Neurobiology.

[39]  R. Yoshimoto,et al.  Simultaneous fluorometric measurement of histamine and tele-methylhistamine levels in rodent brain by high-performance liquid chromatography. , 2004, Analytical biochemistry.

[40]  Gavin Kilpatrick,et al.  Histamine H3 receptors modulate the release of [3H]‐acetylcholine from slices of rat entorhinal cortex: evidence for the possible existence of H3 receptor subtypes , 1992, British journal of pharmacology.

[41]  C. Ganellin,et al.  Histamine and its receptors , 2006, British journal of pharmacology.

[42]  J. Schwartz,et al.  An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: Studies in orexin−/− mice and patients , 2008, Neurobiology of Disease.

[43]  Christopher Browning,et al.  4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists. , 2007, Journal of medicinal chemistry.